Abstract
Purpose
This study investigates the influence of WS® 1442, a special extract of Crataegus leaves with flowers, on the relaxation of rat aorta and human mammarian artery (coronary bypass patients).
Methods
Experiments were performed in the presence and absence (mechanical disruption) of endothelium. In addition, we investigated three fractions of WS® 1442 (fraction A: lipophilic, containing flavonoids and oligomeric procyanidins (OPC), fraction B: hydrophilic, containing flavonoids and low molecular weight OPC, fraction C: hydrophilic, essentially flavonoid-free and rich in high molecular weight OPC).
Results
WS® 1442 induced a concentration-dependent vasodilation in isolated vessel rings that had been precontracted by 10 μM phenylephrine (concentration for halfmaximal relaxation (IC50): rat: 15.1 ± 0.6 μg/ml (n = 7), human: 19.3 ± 3.4 μg/ml (n = 6)). The maximal vasorelaxation induced after application of 100 μg of WS® 1442 was 75.0 ± 5.7% (rat) and 79.2 ± 5.8% (human) of the papaverine (0.1 mM)-induced vasodilation. If the experiments were performed in the presence of l-nitroarginine methylester (10 μM, eNOS-inhibition) or after mechanical disruption of the endothelium, no vasorelaxation was observed in the presence of WS® 1442. The vasorelaxant properties of WS® 1442 were mediated by fraction C. WS® 1442 induced an NO-liberation from human coronary artery endothelial cells as measured by diaminofluorescein. WS® 1442 induced eNOS-activation was due to a phosphorylation at serine 1177. No eNOS-translocation or phosphorylation at serine 114 or threonine 495 was observed after application of WS® 1442.
Conclusions
It is concluded that WS® 1442, induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS phosphorylation at serine 1177.
Similar content being viewed by others
References
Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetycholine. Nature 1980;288:373–6.
Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866–79.
Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 1988;333:664–6.
Gray DM, Marshall I. Novel signal transduction pathway mediating endothelium-dependent beta-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol 1992;107:684–90.
Flemming I, Busse R. Molecular mechanisms involved in the regulation of the edothelial nitric oxide synthase. Am J Physiol 2003;284:R1–12.
Llorens S, Jordan J, Nava E. The nitric oxide pathway in the cardiovascular system. J Physiol Biochem 2002;58:179–88.
Kim SH, Kang KW, Kim KW, Kim ND. Procyanidins in Crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta. Life Sci 2000;67:121–31.
Chen ZY, Zhang ZS, Kwan KY, Zhu M, Ho WKK, Huang Y. Endothelium-dependent relaxation induced by hawthorn extract in rat mesenteric artery. Life Sci 1998;63: 1983–91.
Schroder D, Weiser M, Klein P. Efficacy of a homeopathic Crataegus preparation compare with usual therapy for mild (NYHA II) cardiac insufficience: results of an observational study. Eur J Heart Failure 2003;5:319–26.
Leuchtgens H. Crataegus-Spezialextrakt WS 1442 bei Herzinsuffizienz NYHA II. Fortschr Med 1993;111:352–4.
Weikl A, Assmus K-D, Neukum-Schmidt A, Schmitz J, Zapfe G, Noh HS, et al. Crataegus special extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med 1996;114:291–6.
Tauchert M. Efficacy and safety of Crataegus extract WS 1442 in comparison with placeo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002;143:910–5.
Chatterjee SS, Koch E, Jaggy HEW, Krzeminski T. In vitro und in vivo Untersuchungen zur kardioprotektiven Wirkung von oligomeren Procyanidinen in einem Crataegus-Extrakt (WS 1442) aus Blättern und Blüten. Arzneimittelforschung 1997;47:821–5.
Schwinger RHG, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000;35:700–7.
Kojima H, Sakurai K, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, et al. Development of a fluorescent indicator for nitric oxide based on the fluorescein chromophore. Chem Pharm Bull (Tokyo) 1998;46:373–5.
Bloch W, Mehlhorn U, Krahwinkel A, Reiner M, Dittrich M, Schmidt A, et al. Ischemia increases detectable endothelial nitric oxide synthase in rat and human myocardium. Nitric Oxide 2001;5:317–33.
Vierling W, Brand N, Gaedcke F, Sensch KH, Schneider E, Scholz M. Investigation of the pharmaceutical and pharmacological equivalence of different hawthorn extracts. Phytomedicine 2003;10:8–16.
Fitzpatrick DF, Bing B, Maggi DA, Fleming RC, O'Malley RM. Vasodilating procyanidins derived from grape seeds. Ann N Y Acad Sci 2002;957:78–89.
Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 1998;32:509–15.
Corder R, Warburton RC, Khan NQ, Brown RE, Wood EG, Lees DM. The procyanidin-induced pseudo laminar shear stress response: a new concept for the reversal of endothelial dysfunction. Clin Sci (Lond) 2004;107:513–7.
Kenny TP, Keen CL, Jones P, Kung HJ, Schmitz HH, Gershwin ME. Pentameric procyanidins isolated from Theobroma cacao seeds selectively downregulate ErbB2 in human aortic endothelial cells. Exp Biol Med 2004;229:255–63.
Waldron GJ, Cole WC. Activation of vascular smooth muscle K+ channels by endothelium-derived relaxing factors. Clin Exp Pharmacol Physiol 1999;26:180–4.
Walker AF, Marakis G, Morris AP, Robinson PA. Promising hypotensive double-blind pilot study of mild, essential hypertension. Phytother Res 2002;16:48–54.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brixius, K., Willms, S., Napp, A. et al. Crataegus Special Extract WS® 1442 Induces an Endothelium-Dependent, NO-mediated Vasorelaxation via eNOS-Phosphorylation at Serine 1177. Cardiovasc Drugs Ther 20, 177–184 (2006). https://doi.org/10.1007/s10557-006-8723-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-006-8723-7